Generalized Pairwise Comparisons to Assess Treatment Effects JACC Review Topic of the Week

被引:7
作者
Verbeeck, Johan [1 ,7 ]
De Backer, Mickael [2 ]
Verwerft, Jan [3 ,4 ]
Salvaggio, Samuel [2 ]
Valgimigli, Marco [5 ]
Vranckx, Pascal [3 ,4 ]
Buyse, Marc [1 ,2 ]
Brunner, Edgar [6 ]
机构
[1] Univ Hasselt, Interuniv Inst Biostat & Stat Bioinformat I BioSt, Data Sci Inst, Hasselt, Belgium
[2] Int Drug Dev Inst IDDI, Louvain La Neuve, Belgium
[3] Jessa Hosp Hasselt, Hasselt Heart Ctr, Dept Cardiol & Crit Care Med, Hasselt, Belgium
[4] Univ Hasselt, Fac Med & Life Sci, Hasselt, Belgium
[5] Univ Lugano, Univ Svizzera Italiana, Cardioctr Inst, Ente Osped Cantonale, Lugano, Switzerland
[6] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany
[7] Univ Hasselt, DSI, I BioStat, Agoralaan Gebouw D, B-3590 Hasselt, Belgium
关键词
absolute treatment effect; biostatistics; clinical trials; composite endpoints; endpoint determinations; generalized pairwise comparisons; net treatment benefit; randomized controlled trials as topic; relative treatment effect; success odds; survival analysis; win ratio; COMPOSITE END-POINTS; CEREBRAL EMBOLIC PROTECTION; AORTIC-VALVE-REPLACEMENT; WIN RATIO APPROACH; CLINICAL-TRIALS; HEART-FAILURE; RANDOMIZED EVALUATION; OUTCOMES; DEVICE;
D O I
10.1016/j.jacc.2023.06.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials.
引用
收藏
页码:1360 / 1372
页数:13
相关论文
共 49 条
[1]   The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial [J].
Abdalla, Safa ;
Montez-Rath, Maria E. ;
Parfrey, Patrick S. ;
Chertow, Glenn M. .
CONTEMPORARY CLINICAL TRIALS, 2016, 48 :119-124
[2]   Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency [J].
Anker, Stefan D. t ;
Schroeder, Stefan ;
Atar, Dan ;
Bax, Jeroen J. ;
Ceconi, Claudio ;
Cowie, Martin R. ;
AdamCrisp ;
Dominjon, Fabienne ;
Ford, Ian ;
Ghofrani, Hossein-Ardeschir ;
Gropper, Savion ;
Hindricks, Gerhard ;
Hlatky, Mark A. ;
Holcomb, Richard ;
Honarpour, Narimon ;
Jukema, J. Wouter ;
Kim, Albert M. ;
Kunz, Michael ;
Lefkowitz, Martin ;
Le Floch, Chantal ;
Landmesser, Ulf ;
McDonagh, Theresa A. ;
McMurray, John J. ;
Merkely, Bela ;
Packer, Milton ;
Prasad, Krishna ;
Revkin, James ;
Rosano, Giuseppe M. C. ;
Somaratne, Ransi ;
Stough, Wendy Gattis ;
Voors, Adriaan A. ;
Ruschitzka, Frank .
EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (05) :482-489
[3]  
[Anonymous], 2017, Guideline on multiplicity issues in clinical trials
[4]  
[Anonymous], 1998, INT C HARM E9 EXP WO
[5]   Composite End Points in Clinical Research A Time for Reappraisal [J].
Armstrong, Paul W. ;
Westerhout, Cynthia M. .
CIRCULATION, 2017, 135 (23) :2299-+
[6]  
McDonagh Theresa A, 2021, Eur Heart J, V42, P3599, DOI [10.1002/ejhf.2333, 10.1016/j.rec.2022.05.005, 10.1093/eurheartj/ehab368]
[7]   Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II) [J].
Berry, Natalia ;
Mauri, Laura ;
Feldman, Ted ;
Komtebedde, Jan ;
van Veldhuisen, Dirk J. ;
Solomon, Scott D. ;
Massaro, Joseph M. ;
Shah, Sanjiv J. .
AMERICAN HEART JOURNAL, 2020, 226 :222-231
[8]   Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial [J].
Berwanger, Otavio ;
Pfeffer, Marc ;
Claggett, Brian ;
Jering, Karola S. ;
Maggioni, Aldo P. ;
Steg, Philippe Gabriel ;
Mehran, Roxana ;
Lewis, Eldrin F. ;
Zhou, Yinong ;
van der Meer, Peter ;
De Pasquale, Carmine ;
Merkely, Bela ;
Filippatos, Gerasimos ;
McMurray, John J., V ;
Granger, Christopher B. ;
Solomon, Scott D. ;
Braunwald, Eugene .
EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 (10) :1918-1927
[9]   Effects of Icosapent Ethyl on Total Ischemic Events From REDUCE-IT [J].
Bhatt, Deepak L. ;
Steg, Ph Gabriel ;
Miller, Michael ;
Brinton, Eliot A. ;
Jacobson, Terry A. ;
Ketchum, Steven B. ;
Doyle, Ralph T. ;
Juliano, Rebecca A. ;
Jiao, Lixia ;
Granowitz, Craig ;
Tardif, Jean-Claude ;
Gregson, John ;
Pocock, Stuart J. ;
Ballantyne, Christie M. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (22) :2791-2802
[10]  
Brunner E, 2020, Arxiv, DOI arXiv:2002.09273